Commit Biologics ApS has appointed Thomas L. F. Montgomery Andresen as chief executive officer as the company prepares a transition into clinical stage. Dr Andresen brings 20 years’ experience building high-value biotech ventures and converting scientific breakthroughs into marketable technologies. He co-founded several biotechs including Torque Therapeutics, which was acquired by Repertoire Immune Medicines. Most recently, he served as founding CEO of T-Cypher Bio, an Oxford, UK-based immunotherapy company. Dr Andresen holds a PhD in drug delivery from the Technical University of Denmark. Commit is backed by €21.5 million in seed financing from Novo Holdings, Bioqube Ventures and Korys. The company is poised to nominate its first two clinical development candidates - complement-powered immune engagers - in 2026.
Commit Biologics announced the appointment on 11 March 2026.
Copyright 2026 Evernow Publishing Ltd.